| Followers | 41 |
| Posts | 1069 |
| Boards Moderated | 0 |
| Alias Born | 02/02/2021 |
Wednesday, June 01, 2022 10:36:28 AM
Oh, and this quote attributed to Powerscourt:
Look at the behavior of NWBO leading up to and following the LL/Mulholland NYAS presentation. Cryptic PRs announcing it, without detail. Slides posted on a 3rd party site instead of NWBOs site. No mention of the sponsor on the slide deck. The company has been completely silent since. All seemingly to avoid running afoul of a journal's embargo. But the LL/Mulholland presentation itself was within a common embargo exception permitting scientists/clinicians to present their research to scientists are a science conference.
But now, the company/sponsor NWBO has booked the Industry Theater, which is peripheral to the ASCO science conference, in the name of the company/sponsor's employee/CTO Bosch, during which "Professor Keyoumars Ashkan of Kings College Hospital will be discussing the results of this groundbreaking cancer vaccine study.”
No way he will be if the embargo is still in place.....
“I am looking forward to ASCO next week where Professor Keyoumars Ashkan of Kings College Hospital will be discussing the results of this groundbreaking cancer vaccine study.”
Look at the behavior of NWBO leading up to and following the LL/Mulholland NYAS presentation. Cryptic PRs announcing it, without detail. Slides posted on a 3rd party site instead of NWBOs site. No mention of the sponsor on the slide deck. The company has been completely silent since. All seemingly to avoid running afoul of a journal's embargo. But the LL/Mulholland presentation itself was within a common embargo exception permitting scientists/clinicians to present their research to scientists are a science conference.
But now, the company/sponsor NWBO has booked the Industry Theater, which is peripheral to the ASCO science conference, in the name of the company/sponsor's employee/CTO Bosch, during which "Professor Keyoumars Ashkan of Kings College Hospital will be discussing the results of this groundbreaking cancer vaccine study.”
No way he will be if the embargo is still in place.....
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
